You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
德琪醫藥-B(06996.HK)治療骨髓增生MDS藥物獲內地批准II期試驗
阿思達克 03-30 10:42
德琪醫藥-B(06996.HK)公布,國家藥監局已批准一項開放性II期試驗,旨在評估新一代選擇性核輸出抑制劑(SINE)化合物ATG-016治療高風險骨髓增生異常綜合症(MDS)患者的安全性、耐受性及有效性。 SINE化合物為主要核輸出蛋白Exportin 1(XPO1)的抑制劑。目前,有三款口服SINE化合物正處於臨床開發階段,即ATG-010(selinexor)、ATG-016(eltanexor)及ATG-527(verdinexor)。德琪醫藥已經向Karyopharm獲得該三款藥物在亞太區多個市場的獨家許可。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account